Drug Profile
Research programme: small molecule acne therapeutics - Pfizer/Ortho Dermatologics
Latest Information Update: 02 Aug 2017
Price :
$50
*
At a glance
- Originator Anacor Pharmaceuticals; Medicis Pharmaceutical Corporation
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acne
Most Recent Events
- 27 Jul 2017 Valeant Pharmaceuticals International acquired Ortho Dermatologics in 2011 and changed the name of the later to Valeant Dermatology. Subsequently, in July 2017, it was rebranded to Ortho Dermatologics
- 16 Jul 2016 No recent reports of development identified for research development in Acne in USA
- 24 Jun 2016 Anacor Pharmaceuticals has been acquired by Pfizer